Claes M. Karlsson

Solna, AB 17165, Sweden

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 13 publications

Is conditionally automated driving a bad idea? Observations from an on-road study in automated vehicles with multiple levels of driving automation.

Is conditionally automated driving a bad idea? Observations from an on-road study in automated vehicles with multiple levels of driving automation.

Journal: Applied ergonomics

Published: November 18, 2024

Bridging the Divide: A Review on the Implementation of Personalized Cancer Medicine.

Bridging the Divide: A Review on the Implementation of Personalized Cancer Medicine.

Journal: Journal of personalized medicine

Published: April 11, 2024

The BioLymph study - implementing precision medicine approaches in lymphoma diagnostics, treatment and follow-up: feasibility and first results.

The BioLymph study - implementing precision medicine approaches in lymphoma diagnostics, treatment and follow-up: feasibility and first results.

Journal: Acta oncologica (Stockholm, Sweden)

Published: July 07, 2023

Author Correction: The Molecular Tumor Board Portal supports clinical decisions and automated reporting for precision oncology.

Author Correction: The Molecular Tumor Board Portal supports clinical decisions and automated reporting for precision oncology.

Journal: Nature cancer

Published: April 22, 2022

The Molecular Tumor Board Portal supports clinical decisions and automated reporting for precision oncology.

The Molecular Tumor Board Portal supports clinical decisions and automated reporting for precision oncology.

Journal: Nature cancer

Published: April 07, 2021

Long-term real-world results of ibrutinib therapy in patients with relapsed or refractory chronic lymphocytic leukemia: 30-month follow up of the Swedish compassionate use cohort.

Long-term real-world results of ibrutinib therapy in patients with relapsed or refractory chronic lymphocytic leukemia: 30-month follow up of the Swedish compassionate use cohort.

Journal: Haematologica

Published: December 06, 2018

First-line therapy in chronic lymphocytic leukemia: a Swedish nation-wide real-world study on 1053 consecutive patients treated between 2007 and 2013.

First-line therapy in chronic lymphocytic leukemia: a Swedish nation-wide real-world study on 1053 consecutive patients treated between 2007 and 2013.

Journal: Haematologica

Published: June 21, 2018

Real-world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: data from 95 consecutive patients treated in a compassionate use program. A study from the Swedish Chronic Lymphocytic Leukemia Group.

Real-world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: data from 95 consecutive patients treated in a compassionate use program. A study from the Swedish Chronic Lymphocytic Leukemia Group.

Journal: Haematologica

Published: February 17, 2016

Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study.

Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study.

Journal: The Lancet. Oncology

Published: September 25, 2015

Oncogene-induced senescence underlies the mutual exclusive nature of oncogenic KRAS and BRAF.

Oncogene-induced senescence underlies the mutual exclusive nature of oncogenic KRAS and BRAF.

Journal: Oncogene

Published: September 13, 2014

Wild-type KRAS inhibits oncogenic KRAS-induced T-ALL in mice.

Wild-type KRAS inhibits oncogenic KRAS-induced T-ALL in mice.

Journal: Leukemia

Published: July 18, 2014

Outcomes of patients with fludarabine-refractory chronic lymphocytic leukemia: a population-based study from a well-defined geographic region.

Outcomes of patients with fludarabine-refractory chronic lymphocytic leukemia: a population-based study from a well-defined geographic region.

Journal: Leukemia & lymphoma

Published: November 19, 2013

Showing 1-12 of 13

Last Updated: 09/26/2026